-
公开(公告)号:UY27706A1
公开(公告)日:2003-10-31
申请号:UY27706
申请日:2003-03-07
Applicant: ABBOTT LAB
Inventor: DAANEN JEROME F , COWART MARLON D , BHATIA PRAMILA A , STEWART ANDREW O , PATEL MEENA V , KOLASA TEODOZYJ , BRIONI JORGE D , ROHDE JEFFREY , ENGSTROM KENNETH M
IPC: C07D401/06 , C07D403/00
Abstract: Uso de compuestos de fórmula ( I ) para el tratamiento de la disfunción sexual y composiciones que contienen compuestos de fórmula ( I ) para el tratamiento de la disfunción sexual.
-
公开(公告)号:AU2003219981A1
公开(公告)日:2003-09-22
申请号:AU2003219981
申请日:2003-03-04
Applicant: ABBOTT LAB
Inventor: COWART MARLON D , BHATIA PRAMILA A , DAANEN JEROME F , STEWART ANDREW O , PATEL MEENA V , KOLASA TEODOZYJ , BRIONI JORGE D , ROHDE JEFFREY , ENGSTROM KENNETH M
IPC: A61K31/496 , C07D401/12 , C07D403/12 , A61K31/505 , C07D235/14 , C07D401/14 , C07D417/12
-
公开(公告)号:CA2478028A1
公开(公告)日:2003-09-18
申请号:CA2478028
申请日:2003-03-04
Applicant: ABBOTT LAB
Inventor: DAANEN JEROME F , STEWART ANDREW O , PATEL MEENA V , BHATIA PRAMILA A , ENGSTROM KENNETH M , ROHDE JEFFREY , COWART MARLON D , BRIONI JORGE D , KOLASA TEODOZYJ
IPC: A61K31/496 , C07D401/12 , C07D403/12 , A61K31/505 , C07D235/14 , C07D401/14 , C07D417/12
Abstract: The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.
-
74.
公开(公告)号:NZ501808A
公开(公告)日:2002-12-20
申请号:NZ50180898
申请日:1998-08-10
Applicant: ABBOTT LAB
Inventor: KORT MICHAEL E , BASHA ANWER , KOLASA TEODOZYJ , LIU HUAQING , MCCARTY CATHERINE M , PATEL MEENA V , ROHDE JEFFREY J , BLACK LAWRENCE A
IPC: C07D237/14 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/5377 , A61P5/00 , A61P19/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D20060101 , C07D237/10 , C07D237/16 , C07D237/18 , C07D237/20 , C07D237/22 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/12 , C07F9/547 , C07F9/6509 , C07F11/00
Abstract: A compound of formula (I); wherein: X is O, S, NR4, N-ORa, or N-NRbRc; R is H, alkyl, alkenyl, alkynyl, alkylcarbonylalkyl, alkylsulfonylalkyl, alkylsulfonylarylalkyl, alkoxy, alkoxyalkyl, carboxy, carboxyalkyl, cyanoalkyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, arylalkoxy, arylhaloalkyl, arylhydroxyalkyl, aryloxy, aryloxyhydroxyalkyl, aryloxyhaloalkyl, arylcarbonylalkyl, haloalkoxyhydroxyalkyl, heterocyclic, heterocyclic alkyl, heterocyclic alkoxy, heterocyclic oxy, -C(O)R5, (CH2)nC(O)R5, -R6-R7, -(CH2)nCH(OH)R5, -(CH2)nCH(ORd)R5, -(CH2)nC(NORd)R5, (CH2)nC(NRd)R5, -(CH2)nCH(NORd)R5, -(CH2)nCH(NRdRe)R5, -(CH2)nCºC-R7, (CH2)n[CH(CX'3)]m-(CH2)n-CX'3, -(CH2)n(CX'2)m-(CH2)n-CX'3, -(CH2)n[CH(CX'3)]m-(CH2)n-R8, (CH2)n(CHX'2)m-(CH2)nR8, -(CH2)n(CHX')m-(CH2)n-CX'3, -(CH2)n(CHX')m-(CH2)n-R8, and (CH2)nR20. At least one of R1, R2 and R3 is selected from formula (II) or (III), shown. The remaining two of the groups of R1 and R3, are independently H, hydroxy, hydroxyalkyl, halogen, alkyl, alkenyl, alkynyl, alkylamino, alkenyloxy, alkylthio, alkylthioalkoxy, alkoxy, alkoxyalkyl, alkoxyalkylamino, alkoxyalkoxy, amido, amidoalkyl, haloalkyl, haloalkenyloxy, haloalkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, cycloalkenylalkoxy, cycloalkylalkoxy, cycloalkylalkylamino, cycloalkylamino, cycloalkyloxy, cycloalkylidenealkyl, amino, aminocarbonyl, aminoalkoxy, aminocarbonylalkyl, alkylaminoaryloxy, dialkylamino, dialkylaminoaryloxy, arylamino, arylalkylamino, diarylamino, aryl, arylalkyl, arylalkylthio, arylalkenyl, arylalkynyl, arylalkoxy, aryloxy, heterocyclic, heterocyclic alkyl, heterocyclic(alkyl)amino, heterocyclic alkoxy, heterocyclic amino, heterocyclic oxy, heterocyclic thio, hydroxyalkylamino, hydroxyalkoxy, hydroxyalkylthio, mercaptoalkoxy, oxoalkoxy, cyano, nitro, aryloxyalkyl, alkylthioalkyl, arylthioalkyl, heterocyclic(alkyl) and Y, wherein Y is -OR14, -SR14, -C(R16)(R17)(R14), -C(O)NR21R14, -C(O)R14, -C(O)OR14, -NH(R14), -NC(O)R14,-N=CR21R14, -N-R19R14. R2 is H, hydroxy, hydroxyalkyl, halogen, alkyl, alkenyl, alkynyl, alkylamino, alkenyloxy, alkylthio, alkylthioalkoxy, alkoxy, alkoxyalkyl, alkoxyalkylamino, alkoxyalkoxy, amido, amidoalkyl, haloalkyl, haloalkenyloxy, haloalkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, cycloalkenylalkoxy, cycloalkylalkoxy, cycloalkylalkylamino, cycloalkylamino, cycloalkyloxy, cycloalkylidenealkyl, amino, aminocarbonyl, aminoalkoxy, aminocarbonylalkyl, alkylaminoaryloxy, dialkylamino, dialkylaminoaryloxy, arylamino, arylalkylamino, diarylamino, aryl, arylalkyl, arylalkylthio, arylalkenyl, arylalkynyl, arylalkoxy, aryloxy, heterocyclic, heterocyclic alkyl, heterocyclic(alkyl)amino, heterocyclic alkoxy, heterocyclic amino, heterocyclic oxy, heterocyclic thio, hydroxyalkylamino, hydroxyalkoxy, hydroxyalkylthio, mercaptoalkoxy, oxoalkoxy, cyano, nitro and Y, wherein Y is -OR14, -SR14, -C(R16)(R17)(R14), -C(O)NR21R14, -C(O)R14, -C(O)OR14, -NH(R14), -NC(O)R14,-N=CR21R14, -NR19R14. Also described is a pharmaceutical composition comprising the compound of formula (I). The compounds of formula (I) are useful for inhibiting prostaglandin biosynthesis. The compounds of formula (I) are particularly useful for treating pain, fever, inflammation, rheumatoid arthritis, osteoarthritis and adhesions.
-
公开(公告)号:HU0105248A2
公开(公告)日:2002-07-29
申请号:HU0105248
申请日:1999-10-27
Applicant: ABBOTT LAB
Inventor: BASHA ANWER , BLACK LAWRENCE , COGHLAN MICHAEL J , KOLASA TEODOZYJ , KORT MICHAEL E , LIU HUAQING , MCCARTY CATHERINE M , PATEL MEENA V , ROHDE JEFFREY J , STEWART ANDREW O
IPC: A61K31/50 , A61K31/501 , A61P19/02 , A61P25/04 , A61P29/00 , A61P35/00 , C07D237/14 , C07D237/16 , C07D237/18 , C07D237/22 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/04 , C07D413/12 , C07D417/06
Abstract: The present invention describes pyridazinone compounds of formula (I) which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectively of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).
-
公开(公告)号:CZ20011481A3
公开(公告)日:2001-09-12
申请号:CZ20011481
申请日:1999-10-27
Applicant: ABBOTT LAB
Inventor: BLACK LAWRENCE A , BASHA ANWER , KOLASA TEODOZYJ , KORT MICHAEL E , LIU HUAQING , MCCARTY CATHERINE M , PATEL MEENA V , ROHDE JEFFEY J , COGHLAN MICHAEL J , STEWART ANDREW O
IPC: A61K31/50 , A61K31/501 , A61P19/02 , A61P25/04 , A61P29/00 , A61P35/00 , C07D237/14 , C07D237/16 , C07D237/18 , C07D237/22 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/04 , C07D413/12 , C07D417/06
Abstract: The present invention describes pyridazinone compounds of formula (I) which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectively of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).
-
公开(公告)号:CA2397768A1
公开(公告)日:2001-08-23
申请号:CA2397768
申请日:2001-02-02
Applicant: ABBOTT LAB
Inventor: BUCKNER STEVEN A , BRUNE MICHAEL E , BRIONI JORGE D , KOLASA TEODOZYJ , SULLIVAN JAMES P
IPC: A61K45/00 , A61K31/00 , A61K31/137 , A61K31/4164 , A61K31/4174 , A61P13/00 , A61P13/02 , A61P43/00
Abstract: The following disclosure relates to a method of treating incontinence with a compound having a specific a1A adrenoceptor profile.
-
公开(公告)号:NO20000863D0
公开(公告)日:2000-02-22
申请号:NO20000863
申请日:2000-02-22
Applicant: ABBOTT LAB
Inventor: BLACK LAWRENCE A , BASHA ANWER , KOLASA TEODOZYJ , KORT MICHAEL E , LIU HUAQING , MCCARTY CATHERINE M , PATEL MEENA V , ROHDE JEFFREY J
IPC: C07D237/14 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/5377 , A61P5/00 , A61P19/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D20060101 , C07D237/10 , C07D237/16 , C07D237/18 , C07D237/20 , C07D237/22 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/12 , C07F9/547 , C07F9/6509 , C07F11/00 , C07D
Abstract: In the present invention, there are described pyridazinone compounds, which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1), which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).
-
公开(公告)号:NO20000863A
公开(公告)日:2000-02-22
申请号:NO20000863
申请日:2000-02-22
Applicant: ABBOTT LAB
Inventor: BLACK LAWRENCE A , BASHA ANWER , KOLASA TEODOZYJ , KORT MICHAEL E , LIU HUAQING , MCCARTY CATHERINE M , PATEL MEENA V , ROHDE JEFFREY J
IPC: C07D237/14 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/5377 , A61P5/00 , A61P19/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D20060101 , C07D237/10 , C07D237/16 , C07D237/18 , C07D237/20 , C07D237/22 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/12 , C07F9/547 , C07F9/6509 , C07F11/00
CPC classification number: C07D401/06 , C07D237/14 , C07D237/18 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/06 , C07D409/06 , C07D409/12 , C07D417/06
-
公开(公告)号:CA2578858A1
公开(公告)日:1999-03-04
申请号:CA2578858
申请日:1998-08-10
Applicant: ABBOTT LAB
Inventor: MCCARTY CATHERINE M , PATEL MEENA V , LIU HUAQING , KORT MICHAEL E , KOLASA TEODOZYJ , BLACK LAWRENCE A , BASHA ANWER , ROHDE JEFFREY J
IPC: C07D237/14 , A61K31/50 , A61K31/501 , C07D237/18
-
-
-
-
-
-
-
-
-